163 related articles for article (PubMed ID: 27247756)
41. The biological rationale and clinical efficacy of inhibition of signaling kinases in chronic lymphocytic leukemia.
de Weerdt I; Eldering E; van Oers MH; Kater AP
Leuk Res; 2013 Jul; 37(7):838-47. PubMed ID: 23597579
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
[TBL] [Abstract][Full Text] [Related]
43. Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases.
Blomgren P; Chandrasekhar J; Di Paolo JA; Fung W; Geng G; Ip C; Jones R; Kropf JE; Lansdon EB; Lee S; Lo JR; Mitchell SA; Murray B; Pohlmeyer C; Schmitt A; Suekawa-Pirrone K; Wise S; Xiong JM; Xu J; Yu H; Zhao Z; Currie KS
ACS Med Chem Lett; 2020 Apr; 11(4):506-513. PubMed ID: 32292557
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.
Kutsch N; Pallasch C; Tausch E; Böhme V; Ritgen M; Liersch R; Wacker A; Jacobs G; Trappe RU; Dreger P; Fischer K; Fink AM; Stilgenbauer S; Zhai S; Li B; Jürgensmeier JM; Rajakumaraswamy N; Bhargava P; Hallek M; Eichhorst BF
Hemasphere; 2022 Apr; 6(4):e692. PubMed ID: 35284802
[No Abstract] [Full Text] [Related]
45. Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
Brown JR; Hallek MJ; Pagel JM
Am Soc Clin Oncol Educ Book; 2016; 35():e387-98. PubMed ID: 27249745
[TBL] [Abstract][Full Text] [Related]
46. New Agents to Treat Chronic Lymphocytic Leukemia.
Roberts AW; Davids MS; Seymour JF
N Engl J Med; 2016 Jun; 374(22):2186-7. PubMed ID: 27248631
[No Abstract] [Full Text] [Related]
47. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
[TBL] [Abstract][Full Text] [Related]
48. B-cell subsets, signaling and their roles in secretion of autoantibodies.
Iwata S; Tanaka Y
Lupus; 2016 Jul; 25(8):850-6. PubMed ID: 27252261
[TBL] [Abstract][Full Text] [Related]
49. New Agents to Treat Chronic Lymphocytic Leukemia.
Zaman F; Savendahl L
N Engl J Med; 2016 Jun; 374(22):2185. PubMed ID: 27248632
[No Abstract] [Full Text] [Related]
50. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Barrientos JC
Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
[TBL] [Abstract][Full Text] [Related]
51. The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein.
Walliser C; Hermkes E; Schade A; Wiese S; Deinzer J; Zapatka M; Désiré L; Mertens D; Stilgenbauer S; Gierschik P
J Biol Chem; 2016 Oct; 291(42):22136-22148. PubMed ID: 27542411
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
[TBL] [Abstract][Full Text] [Related]
53. Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial.
Strati P; Lanasa M; Call TG; Leis JF; Brander DM; LaPlant BR; Pettinger AM; Ding W; Parikh SA; Hanson CA; Chanan-Khan AA; Bowen DA; Conte M; Kay NE; Shanafelt TD
Lancet Haematol; 2016 Sep; 3(9):e407-14. PubMed ID: 27570087
[TBL] [Abstract][Full Text] [Related]
54. Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia.
Lutz M; Schulze AB; Rebber E; Wiebe S; Zoubi T; Grauer OM; Keßler T; Kerkhoff A; Lenz G; Berdel WE
Cancer Res Treat; 2017 Apr; 49(2):548-552. PubMed ID: 27456945
[TBL] [Abstract][Full Text] [Related]
55. SLP76 integrates into the B-cell receptor signaling cascade in chronic lymphocytic leukemia cells and is associated with an aggressive disease course.
Dezorella N; Katz BZ; Shapiro M; Polliack A; Perry C; Herishanu Y
Haematologica; 2016 Dec; 101(12):1553-1562. PubMed ID: 27443285
[TBL] [Abstract][Full Text] [Related]
56. Platelets and tyrosine kinase inhibitors: clinical features, mechanisms of action, and effects on physiology.
Zheng TJ; Parra-Izquierdo I; Reitsma SE; Heinrich MC; Larson MK; Shatzel JJ; Aslan JE; McCarty OJT
Am J Physiol Cell Physiol; 2022 Oct; 323(4):C1231-C1250. PubMed ID: 35938677
[TBL] [Abstract][Full Text] [Related]
57. Proteomics and Drug Repurposing in CLL towards Precision Medicine.
Mavridou D; Psatha K; Aivaliotis M
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298607
[TBL] [Abstract][Full Text] [Related]
58. Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia.
Loftus JP; Yahiaoui A; Brown PA; Niswander LM; Bagashev A; Wang M; Schauf A; Tannheimer S; Tasian SK
Haematologica; 2021 Apr; 106(4):1067-1078. PubMed ID: 32414848
[TBL] [Abstract][Full Text] [Related]
59. Role of spleen tyrosine kinase in liver diseases.
Kurniawan DW; Storm G; Prakash J; Bansal R
World J Gastroenterol; 2020 Mar; 26(10):1005-1019. PubMed ID: 32205992
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
